| scholarly article | Q13442814 |
| P2093 | author name string | Daniel J Wong | |
| Joseph D Feuerstein | |||
| Eve M Roth | |||
| Vitaliy Y Poylin | |||
| P2860 | cites work | American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection | Q46063298 |
| Influence of adalimumab treatment on anastomotic strength, degree of inflammation, and collagen formation: an experimental study on the small intestine of rabbits | Q46074566 | ||
| Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis | Q46152475 | ||
| Trends in surgery for Crohn's disease in the era of infliximab | Q46223812 | ||
| Impact of inflammatory bowel disease on post-cholecystectomy complications and hospitalization costs: a Nationwide Inpatient Sample study | Q46386168 | ||
| Meta-analysis: pre-operative infliximab treatment and short-term post-operative complications in patients with ulcerative colitis | Q46400709 | ||
| Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 | ||
| Colectomy rate in acute severe ulcerative colitis in the infliximab era. | Q46601124 | ||
| Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centers | Q46763092 | ||
| Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? | Q46840604 | ||
| A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization | Q46846798 | ||
| Infliximab as rescue therapy in hospitalised patients with steroid-refractory acute ulcerative colitis: a long-term follow-up of 211 Swedish patients. | Q46875109 | ||
| Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey | Q47389831 | ||
| Market share and costs of biologic therapies for inflammatory bowel disease in the USA. | Q47430297 | ||
| The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort | Q47733622 | ||
| Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study. | Q47899983 | ||
| Pelvic sepsis after IPAA adversely affects function of the pouch and quality of life | Q48009853 | ||
| Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. | Q48095368 | ||
| Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. | Q48172806 | ||
| Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectives | Q26740356 | ||
| Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper | Q26783978 | ||
| A review of the impact of biologics on surgical complications in Crohn's disease | Q26865009 | ||
| Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease | Q26866281 | ||
| Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta-analysis | Q27010300 | ||
| Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: A narrative review | Q28079965 | ||
| Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial | Q28202504 | ||
| Infliximab maintenance therapy for fistulizing Crohn's disease | Q28246982 | ||
| A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease | Q28270722 | ||
| Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 | ||
| Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? | Q33564081 | ||
| Infliximab's influence on anastomotic strength and degree of inflammation in intestinal surgery in a rabbit model. | Q33597698 | ||
| Review article: the efficacy of infliximab in Crohn's disease--healing of fistulae | Q33793937 | ||
| Infliximab for the treatment of fistulas in patients with Crohn's disease | Q33860666 | ||
| Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up | Q34225622 | ||
| Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial | Q34574245 | ||
| Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin | Q34842148 | ||
| Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years | Q35026410 | ||
| Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. | Q35188609 | ||
| Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn's disease: A meta-analysis of observational studies | Q35540491 | ||
| Management of perianal fistulas in Crohn's disease: an up-to-date review | Q35558085 | ||
| Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County | Q35596600 | ||
| Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. | Q35743069 | ||
| Risk of fecal diversion in complicated perianal Crohn's disease | Q35751519 | ||
| Review article: The medical treatment of Crohn's perianal fistulas. | Q35758318 | ||
| The Future of IBD Therapy: Where Are We and Where Should We Go Next? | Q35959487 | ||
| Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial | Q35986231 | ||
| Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT). | Q36058400 | ||
| Review article: recurrence of Crohn's disease after surgery - the need for treatment of new lesions | Q36589403 | ||
| Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. | Q36793930 | ||
| Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? | Q36953342 | ||
| Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults | Q37035957 | ||
| Early surgery in Crohn's disease a benefit in selected cases. | Q37089435 | ||
| The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery | Q37197292 | ||
| Adalimumab for the treatment of fistulas in patients with Crohn's disease | Q37209889 | ||
| Early postoperative complications have long-term impact on quality of life after restorative proctocolectomy. | Q37327893 | ||
| A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab | Q37373219 | ||
| Perianal Crohn's disease: challenges and solutions | Q37641311 | ||
| Surgery, Crohn's disease, and the biological era: has there been an impact? | Q37816853 | ||
| Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals | Q37832838 | ||
| Surgery for adult Crohn's disease: what is the actual risk? | Q37879341 | ||
| Perioperative complications in inflammatory bowel disease | Q37889836 | ||
| Postoperative recurrent luminal Crohn's disease: a systematic review | Q37914790 | ||
| Hospitalisations and surgery in Crohn's disease | Q37977910 | ||
| Anti-tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta-analysis | Q37998988 | ||
| Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis | Q38092473 | ||
| Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease | Q38098574 | ||
| When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel | Q38105771 | ||
| Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis | Q38122070 | ||
| Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies | Q38125012 | ||
| The effect of anti-tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review | Q38160684 | ||
| Biologic therapy and surgery for crohn disease | Q38179381 | ||
| Have biologics changed the natural history of Crohn's disease? | Q38223554 | ||
| Systematic review: the combined surgical and medical treatment of fistulising perianal Crohn's disease. | Q38239165 | ||
| An overview of FDA-approved biologics medicines | Q38249104 | ||
| Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies | Q38261535 | ||
| Initial surgical management of ulcerative colitis in the biologic era. | Q38266102 | ||
| Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis | Q38291763 | ||
| National trends of 3- versus 2-stage restorative proctocolectomy for chronic ulcerative colitis. | Q38316920 | ||
| Is Modern Medical Management Changing Ultimate Patient Outcomes in Inflammatory Bowel Disease? | Q38407096 | ||
| Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center | Q38448536 | ||
| How often do IBD patients require resection of their intestine? | Q82072155 | ||
| Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease | Q82816860 | ||
| Biological immunomodulators improve the healing rate in surgically treated perianal Crohn's fistulas | Q83260332 | ||
| Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? | Q83389780 | ||
| Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care | Q83767004 | ||
| Postoperative infliximab is not associated with an increase in adverse events in Crohn's disease | Q84382277 | ||
| Ileal disease is associated with surgery for perianal disease in a population-based Crohn's disease cohort | Q84570024 | ||
| Should biologic agents be stopped before surgery for inflammatory bowel disease? | Q85902693 | ||
| Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence | Q87122788 | ||
| Anti-tumor necrosis factor therapy to prevent Crohn's disease recurrence after surgery | Q87306178 | ||
| Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study | Q88546520 | ||
| Disease Course and Colectomy Rate of Ulcerative Colitis: A Follow-up Cohort Study of a Referral Center in Tuscany | Q89278169 | ||
| Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. | Q50543867 | ||
| Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. | Q50552144 | ||
| Crohn's disease management after intestinal resection: a randomised trial. | Q51022261 | ||
| The results of seton drainage combined with anti-TNFα therapy for anal fistula in Crohn's disease. | Q51075051 | ||
| Possible overuse of 3-stage procedures for active ulcerative colitis. | Q51241233 | ||
| The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. | Q51251490 | ||
| Practice parameters for the surgical treatment of ulcerative colitis. | Q51328105 | ||
| Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. | Q51733257 | ||
| Tumor necrosis factor and wound healing. | Q52484542 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. | Q53142048 | ||
| Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics. | Q53329085 | ||
| A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 | ||
| Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. | Q54223290 | ||
| Local injection of Infliximab for the treatment of perianal Crohn's disease | Q57000195 | ||
| Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? | Q57123538 | ||
| Long-term outcome after infliximab for refractory ulcerative colitis | Q57265403 | ||
| The current state of the art for biological therapies and new small molecules in inflammatory bowel disease | Q60017517 | ||
| Course of ulcerative colitis: analysis of changes in disease activity over years | Q72036054 | ||
| Risk factors for intra-abdominal sepsis after surgery in Crohn's disease | Q74194464 | ||
| Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease | Q75414705 | ||
| The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota | Q77810598 | ||
| Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis | Q80269736 | ||
| Early versus late surgery for ileo-caecal Crohn's disease | Q81233664 | ||
| Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy | Q81416000 | ||
| Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease | Q38588669 | ||
| Perioperative use of immunosuppressive medications in patients with Crohn's disease in the new "biological era". | Q38635824 | ||
| Insights on the use of biosimilars in the treatment of inflammatory bowel disease | Q38735477 | ||
| Total abdominal colectomy vs. restorative total proctocolectomy as the initial approach to medically refractory ulcerative colitis | Q38769696 | ||
| Post-operative abdominal complications in Crohn's disease in the biological era: Systematic review and meta-analysis | Q38791996 | ||
| Timing of Last Preoperative Dose of Infliximab Does Not Increase Postoperative Complications in Inflammatory Bowel Disease Patients | Q38820319 | ||
| Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease | Q38932558 | ||
| Patient optimization for surgery relating to Crohn's disease | Q38990782 | ||
| Biosimilars in inflammatory bowel disease: A review of post-marketing experience | Q38996437 | ||
| Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients | Q39062934 | ||
| Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group. | Q39106087 | ||
| The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease | Q39233355 | ||
| As Infliximab Use for Ulcerative Colitis Has Increased, so Has the Rate of Surgical Resection | Q39292875 | ||
| Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study | Q39583647 | ||
| Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. | Q39645051 | ||
| Timing and Indications for Colectomy in Chronic Ulcerative Colitis: Surgical Consideration | Q39830004 | ||
| Anti-TNF Monotherapy for Crohn's Disease: a 13-year Multicentre Experience | Q40070921 | ||
| Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab | Q40118237 | ||
| Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease | Q40285958 | ||
| Has widespread use of biologic and immunosuppressant therapy for ulcerative colitis affected surgical trends? Results of a questionnaire survey of surgical institutions in Japan | Q40431363 | ||
| Twenty-year review of the surgical management of perianal Crohn's disease | Q40508601 | ||
| Emerging trends and risk factors for perianal surgery in Crohn's disease: a 20-year national population-based cohort study | Q40775952 | ||
| Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort | Q41573206 | ||
| Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy | Q42245109 | ||
| Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy | Q42360446 | ||
| Surgical treatment of ulcerative colitis in the biologic therapy era. | Q42728456 | ||
| Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates | Q42962098 | ||
| Long-term effects and colectomy rates in ulcerative colitis patients treated with infliximab: a Danish single center experience | Q43496310 | ||
| Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab | Q44042352 | ||
| Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study | Q44508235 | ||
| Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab | Q44742543 | ||
| Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). | Q44791207 | ||
| Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection | Q44854180 | ||
| Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. | Q44899085 | ||
| Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience | Q45024098 | ||
| Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. | Q45892140 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 77-90 | |
| P577 | publication date | 2019-04-01 | |
| P1433 | published in | Gastroenterology report | Q27725210 |
| P1476 | title | Surgery in the age of biologics | |
| P478 | volume | 7 |
| Q98612726 | Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease |
| Q91893668 | Drug utilization and cost associated with inflammatory bowel disease management in Saudi Arabia |
| Q99556690 | Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis |
| Q92276628 | The Impact of Biologic Therapy on Outcomes of Inflammatory Bowel Disease Surgery |
Search more.